Last Updated: September 25, 2026

Ani Pharms Company Profile


✉ Email this page to a colleague

« Back to Dashboard


What is the competitive landscape for ANI PHARMS

ANI PHARMS has two hundred and forty-eight approved drugs.

There are six US patents protecting ANI PHARMS drugs. There is one tentative approval on ANI PHARMS drugs.

Summary for Ani Pharms
US Patents:6
Tradenames:158
Ingredients:151
NDAs:248

Drugs and US Patents for Ani Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ani Pharms CHLORPROPAMIDE chlorpropamide TABLET;ORAL 088813-001 Oct 19, 1984 DISCN No No ⤷  Start Trial ⤷  Start Trial
Ani Pharms CEFADROXIL cefadroxil/cefadroxil hemihydrate FOR SUSPENSION;ORAL 062698-003 Mar 1, 1989 DISCN No No ⤷  Start Trial ⤷  Start Trial
Ani Pharms NICARDIPINE HYDROCHLORIDE nicardipine hydrochloride CAPSULE;ORAL 074439-001 Dec 10, 1996 DISCN No No ⤷  Start Trial ⤷  Start Trial
Ani Pharms OXYCODONE HYDROCHLORIDE oxycodone hydrochloride CAPSULE;ORAL 205177-001 Mar 31, 2016 AB RX No No ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Ani Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ani Pharms BRETHINE terbutaline sulfate TABLET;ORAL 017849-002 Approved Prior to Jan 1, 1982 3,937,838 ⤷  Start Trial
Ani Pharms ATACAND candesartan cilexetil TABLET;ORAL 020838-004 Jun 4, 1998 5,703,110 ⤷  Start Trial
Ani Pharms ATACAND candesartan cilexetil TABLET;ORAL 020838-001 Jun 4, 1998 5,508,297 ⤷  Start Trial
Ani Pharms INDERAL LA propranolol hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 018553-004 Mar 18, 1987 4,138,475 ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for ANI PHARMS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 32 mg/25 mg ➤ Subscribe 2009-03-06
➤ Subscribe for Injection 200 mcg/vial ➤ Subscribe 2015-05-01
➤ Subscribe Tablets 16 mg/12.5 mg and 32 mg/12.5 mg ➤ Subscribe 2008-06-25
➤ Subscribe for Injection 100 mcg/vial and 500 mcg/vial ➤ Subscribe 2015-04-14
➤ Subscribe Tablets 4 mg, 8 mg, 16 mg and 32 mg ➤ Subscribe 2006-12-22

Supplementary Protection Certificates for Ani Pharms Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1448186 488 Finland ⤷  Start Trial
1109558 SPC/GB08/058 United Kingdom ⤷  Start Trial PRODUCT NAME: RANOLAZINE OR A SALT OR SOLVATE THEREOF; REGISTERED: UK EU/1/08/462/001 20080714; UK EU/1/08/462/002 20080714; UK EU/1/08/462/003 20080714; UK EU/1/08/462/004 20080714; UK EU/1/08/462/005 20080714; UK EU/1/08/462/006 20080714
1912999 14C0076 France ⤷  Start Trial PRODUCT NAME: SIMEPREVIR OU L'UN DE SES SELS, INCLUANT LE SEL DE SODIUM DE SIMEPREVIR; REGISTRATION NO/DATE: EU/1/14/924 20140516
2673237 SPC/GB19/027 United Kingdom ⤷  Start Trial PRODUCT NAME: SODIUM ZIRCONIUM CYCLOSILICATE; REGISTERED: UK EU/1/17/1173(NI) 20180326; UK PLGB17901/0331-0001 20180326; UK PLGB17902/0332-0001 20180326
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.